Effects of ertugliflozin on uric acid and gout‐related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from <scp>VERTIS CV</scp>Vikas S. Sridhar, David Z.I. Cherney, Richard E. Pratley et al.|Diabetes Obesity and Metabolism|2024Cited by 8
Heart Failure Outcomes Captured by Adverse Event Reporting in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Observations from the VERTIS CV TrialAmbarish Pandey, Christopher P. Cannon, Ahmed A. Kolkailah et al.|European Journal of Heart Failure|2025Cited by 1